Company
eMed
eMed publishes brand semaglutide at $149.99 a month — Prescription medication (paid only if approved).
- 1 program
- 1 molecule
- 1 reading
Read from emed.com on September 2, 2026. This page records what the company publishes. It is not a review and takes no position on the company.
Go to eMed
We earn nothing from this link. eMed has no commercial arrangement with Treatment Registry, and its record here is kept to the same standard as every other.
What it costs
first month, including the required fees on record · ◯ $149.99 advertised · Prescription medication (paid only if approved)
Terms
| Membership | Required, $149.99 per month. eMed's Membership Fee $149.99 Per month |
|---|---|
| States | Not disclosed as of September 3, 2026 |
Not yet checked: pharmacy and consultation fee.
Terms can differ between this company’s programs; each entry carries its own.
Programs
Notes
Recorded against this company rather than one program.
September 2, 2026
- 1. This is the clearest example of the two-fee trap the brief warns about, except eMed discloses BOTH figures separately on the same pricing block: 'Application & Screening $49 One-time fee', then 'Prescription Medication From $149.99 Per month (Paid only if approved)', then, as its own separate line, 'eMed's Membership Fee $149.99 Per month.' So a member on the medication pays roughly $49 once plus $149.99/mo for the drug plus another $149.99/mo membership fee — total ~$300/mo, not $149.99. Medication is Wegovy (brand semaglutide), offered as both the injection pen and a newly launched once-daily Wegovy pill (oral); no separate price is shown for the pill. No cancellation/subscription-termination language was found on any crawled page — only a no-returns/no-refunds policy for dispensed products.
Before you act
Cite this
Treatment Registry. (2026). eMed: recorded programs and prices. Last verified September 2, 2026. Retrieved [your access date], from https://treatmentregistry.com/providers/emed